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INTRODUCTION
Undesirable taste is one of the important issues observed with pharmaceutical formulations
specifically with bitter tasting drugs. Effective taste masking can be achieved by various
reported approaches such as fluidized-bed coating, supercritical fluids, complexing agents, or
pro-drug approaches. However, lipid-based formulations have gained interest in recent times
and are applied for numerous purposes such as controlled release, improvement of
swallowability, moisture protection, and taste masking applications.

PURPOSE
The objective of the current study was to investigate the potential of different lipids to mask the
unpleasant/ bitter taste of caffeine citrate by hot melt extrusion techniques.

METHODS
Two lipids, glyceryl dibehenate (Compritol® 888 ATO) and glyceryl palmitostearate (Precirol®
ATO were investigated with caffeine citrate as a model drug. Caffeine citrate was blended
individually with Compritol® and Precirol® at high drug loads. The physical mixtures of drug

• The extrusion process was carried out at higher drug loads
of 90%,80% and 70% (w/w) with lipids in 10%, 20% and
30% (w/w) concentrations, respectively.
• The die plate was removed and the extrudates were
collected as granules with torque in the 2-5% range.
• Thermal behaviour of the physical blend and the extruded
formulations examined by differential scanning calorimetry
(DSC)

showed

the

presence

of

two

characteristic

endothermal peaks for Compritol® formulations,

Figure 2. Gastric dissolution profiles of caffeine citrate with (a) compritol (b)
precirol

• The peak at 168°C shows the presence of crystalline
caffeine citrate and the other at 72.9°C Compritol® melting
point as shown in Figure 3.
• Similarly, for Precirol® formulations, there were two
characteristics peaks observed one at 168°C and the other
at 52°C

(Precirol® melting point).These observations

reveal that caffeine citrate is in crystalline form.

and lipids were extruded using an 11mm co-rotating twin-screw extruder (Process 11 twin
screw extruder, Thermo Fisher Scientific) utilizing Thermo Fischer standard screw

• Dissolution testing in simulated salivary media (pH 6.8)
was used as a primary screening method for assessing the

configuration.
The extrusion was performed over the melting range of 70-75 °C for Compritol® formulations,
and 50-60 °C for Precirol® formulations at a constant screw speed of 50 rpm.
Solid-state characterization of the extrudates was performed by Differential Scanning
Calorimetry (DSC). Further, the flow properties of prepared formulations was studied.
Dissolution studies were performed on the milled extrudates in 500mL of simulated salivary
media (pH 6.8) to assess the extent of drug release in the salivary pH and gastric drug
release was assessed in 0.1N HCl using USP apparatus I (50 rpm).

RESULTS

taste

masking

ability

of

the

formulations.

All

the

formulations showed low drug release (1%-2%) in
simulated salivary media (Figure 1).
• Dissolution studies in 0.1N HCl for 20% (w/w) and 30

Figure 3. DSC thermograms of pure caffeine citrate, pure compritol, pure precirol
and corresponding extrudates

%(w/w) compritol® formulations showed a drug release of
67.83% and 54% respectively at the

end of two hours

CONCLUSIONS

(Figure 2a).While for formulations with 20% (w/w) and 30%
(w/w) precirol® as lipid, the drug release was observed as

•

61.87% and 66.13% respectively (Figure 2b).
• The flow properties of pure caffeine citrate, lipids and the
formulations were predicted using Carr’s compressibility

HME technology.
•

•

Table 1. Compressibility Index and Hausner’s Ratio of pure •
caffeine citrate and the extrudates

Figure 1. Salivary dissolution profiles of caffeine citrate with (a) compritol (b) precirol

Pure caffeine
citrate
Compritol
Precirol
70% API and
30% Compritol
70% API and
30% Precirol

DSC studies indicated the crystalline nature of caffeine citrate in the
formulations.

1.

Formulations

The results from salivary dissolution demonstrated the taste masking ability
of lipids.

index and Hausner’s ratio. The formulations with
precirol® demonstrated good flowability as shown in Table

Caffeine citrate was extruded with various concentrations of lipids using

Compressibility
Index

Hausner’s Ratio

20.8 (fair)

1.25 (fair)

25.04 (passable)
9.90 (excellent)
28.6 (poor)

1.33 (passable)
1.11 (excellent)
1.17 (poor)

Hot melt extrusion can be considered as an efficient method and promising
technique for the development of taste masking formulations by the
incorporation of lipids.

ACKNOWLEDGEMENTS
This project was also partially supported by Grant Number P30GM12273301A1, funded by the National Institute of General Medical Sciences (NIGMS)
a component of the National Institutes of Health (NIH) as one of its Centers of

12.46 (good)

1.14 (good)

Biomedical Research Excellence (COBRE).

